Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

Next Previous
Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Vitiligo
  • Focus Registrational; Therapeutic Use
  • Acronyms Viti-Up
  • Sponsors AbbVie

Most Recent Events

  • 27 Mar 2026 According to an Abbvie media release, data from this trial will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27 to 31 in Denver, Colorado.
  • 03 Feb 2026 According to an AbbVie media release, company has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for a new indication for upadacitinib, supported by data from the phase 3 Viti-Up clinical studies.
  • 29 Oct 2025 Primary endpoint has been met (Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 ( 75% Improvement in F-VASI From Baseline)), according to AbbVie media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top